Literature DB >> 16938146

Functional and psychosocial impairment in adults with undiagnosed ADHD.

Stephen L Able1, Joseph A Johnston, Lenard A Adler, Ralph W Swindle.   

Abstract

BACKGROUND: Identify a group of adults with 'undiagnosed' attention deficit hyperactivity disorder (ADHD) and compare their personal and family medical histories, psychosocial profiles, functional impairment and quality of life with non-ADHD controls. Additionally, compare adults with undiagnosed and diagnosed ADHD to investigate possible reasons why the undiagnosed avoid clinical detection.
METHOD: ICD-9 codes for ADHD in administrative claims records and responses to a telephone-administered adult ADHD screener [the Adult ADHD Self-Report Scale (ASRS)] were used to classify approximately 21000 members of two large managed health-care plans as 'undiagnosed' (no coded diagnosis; ASRS positive) or 'non-ADHD' controls (no coded diagnosis; ASRS negative). Patients identified as 'undiagnosed' ADHD were compared with samples of non-ADHD controls and 'diagnosed' ADHD patients (ICD-9 coded ADHD diagnoses) on the basis of demographics, socio-economic status, past and present mental health conditions, and self-reported functional and psychosocial impairment and quality of life.
RESULTS: A total of 752 'undiagnosed' ADHD subjects, 199 'non-ADHD' controls and 198 'diagnosed' ADHD subjects completed a telephone interview. Overall, the 'undiagnosed' ADHD cohort demonstrated higher rates of co-morbid illness and greater functional impairment than 'non-ADHD' controls, including significantly higher rates of current depression, and problem drinking, lower educational attainment, and greater emotional and interpersonal difficulties. 'Undiagnosed' ADHD subjects reported a different racial composition and lower educational attainment than 'diagnosed' ADHD subjects.
CONCLUSION: Individuals with 'undiagnosed' ADHD manifest significantly greater functional and psychosocial impairment than those screening negative for the disorder, suggesting that ADHD poses a serious burden to adults even when clinically unrecognized.

Entities:  

Mesh:

Year:  2006        PMID: 16938146     DOI: 10.1017/S0033291706008713

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  47 in total

1.  Analysis of patients' preferences: direct assessment and discrete-choice experiment in therapy of adults with attention-deficit hyperactivity disorder.

Authors:  Axel C Mühlbacher; Matthias Nübling
Journal:  Patient       Date:  2010-12-01       Impact factor: 3.883

2.  Adult patients with ADHD differ from healthy controls in implicit, but not explicit, emotion regulation

Authors:  Lukas Materna; Christian Dirk Wiesner; Anna Shushakova; Julia Trieloff; Nathalia Weber; Alva Engell; Ricarda I. Schubotz; Jochen Bauer; Anya Pedersen; Patricia Ohrmann
Journal:  J Psychiatry Neurosci       Date:  2019-09-01       Impact factor: 6.186

Review 3.  The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review.

Authors:  David Coghill
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

4.  Functioning Assessment Short Test (FAST): validity and reliability in adults with attention-deficit/hyperactivity disorder.

Authors:  Sofía Rotger; Vanesa Richarte; Mariana Nogueira; Montse Corrales; Rosa Bosch; Raquel Vidal; Lidia Marfil; Sergi Valero; Eduard Vieta; José Manuel Goikolea; Imma Torres; Adriane Rosa; María Mur; Miguel Casas; Josep Antoni Ramos-Quiroga
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-04-08       Impact factor: 5.270

5.  Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD).

Authors:  E Sobanski; D Sabljic; B Alm; G Skopp; N Kettler; R Mattern; P Strohbeck-Kühner
Journal:  J Neural Transm (Vienna)       Date:  2008-01-16       Impact factor: 3.575

Review 6.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

7.  The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders.

Authors:  Elias Dakwar; Amy Mahony; Martina Pavlicova; Andrew Glass; Daniel Brooks; John J Mariani; John Grabowski; Frances Rudnick Levin
Journal:  J Clin Psychiatry       Date:  2012-11       Impact factor: 4.384

8.  First treatment contact for ADHD: predictors of and gender differences in treatment seeking.

Authors:  Elias Dakwar; Frances R Levin; Mark Olfson; Shuai Wang; Bradley Kerridge; Carlos Blanco
Journal:  Psychiatr Serv       Date:  2014-10-31       Impact factor: 3.084

Review 9.  Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults.

Authors:  Christopher Gibbins; Margaret Weiss
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

10.  Adult ADHD and comorbid depression: A consensus-derived diagnostic algorithm for ADHD.

Authors:  Diane McIntosh; Stan Kutcher; Carin Binder; Anthony Levitt; Angelo Fallu; Michael Rosenbluth
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.